Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,556 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-small Cell Lung Carcinoma (NSCLC) Clear all
Completed Phase 2 Interventional

Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer

NCT01493843
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
pictilisib, Placebo, bevacizumab, carboplatin, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
44
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 14, 2026, 11:22 PM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

NCT06870487
View directory record Official record
Conditions
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
Interventions
PF-08046032, Sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Results available

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03631706
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M7824, Pembrolizumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
25
States / cities
Huntsville, Alabama • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 14, 2026, 11:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

NCT03361228
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB001158, Epacadostat, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 14, 2026, 11:22 PM EDT
Terminated Phase 2 Interventional Results available

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

NCT03232892
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Trametinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 14, 2026, 11:22 PM EDT
Completed No phase listed Observational

Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer

NCT02273336
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Small Cell Lung Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
University of Southern California
Other
Eligibility
Up to 39 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Not applicable Interventional

Healthy Directions After Lung Surgery Pilot

NCT02135211
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung
Interventions
Lifestyle counseling
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 14, 2026, 11:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

NCT04083599
View directory record Official record
Conditions
Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
GEN1042, Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Gemcitabine, Nab paclitaxel, Pemetrexed, Paclitaxel
Biological · Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
23
States / cities
Anchorage, Alaska • Los Alamitos, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692
View directory record Official record
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Ceralasertib, Durvalumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
27
States / cities
Mobile, Alabama • Chandler, Arizona • Los Alamitos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Recruiting Phase 2 Interventional

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

NCT07218601
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Breath sample collection, Research blood collection
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Active, not recruiting Phase 2 Interventional

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

NCT04367311
View directory record Official record
Conditions
Lung Cancer, NSCLC
Interventions
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Drug
Lead sponsor
Nasser Hanna
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Chicago, Illinois • Indianapolis, Indiana • Berkeley Heights, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Not listed Phase 2 Interventional

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00964132
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
NRX194204
Drug
Lead sponsor
NuRx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Fountain Valley, California • La Jolla, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Oct 14, 2026, 11:22 PM EDT
Terminated Phase 3 Interventional Results available

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

NCT02134015
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Patritumab, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
20 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Glendale, Arizona • Duarte, California • La Verne, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 14, 2026, 11:22 PM EDT
Recruiting Not applicable Interventional

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

NCT06576635
View directory record Official record
Conditions
NSCLC
Interventions
Docetaxel, Paclitaxel, Gemcitabine, Pemetrexed, Vinorelbine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Terminated Not applicable Interventional Results available

Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

NCT01799135
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
DCE-MRI scan, Stereotactic Body Radiation Therapy, 4D-CT scan
Other · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 1 Interventional Results available

Phase I Combination Ixabepilone + Cisplatin

NCT00832117
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ixabepilone, Cisplatin
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New Brunswick, New Jersey • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 14, 2026, 11:22 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

NCT05551117
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

NCT05775289
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Detroit, Michigan • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Active, not recruiting Phase 3 Interventional

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574
View directory record Official record
Conditions
Lung Cancer, Non-squamous, Non-small Cell
Interventions
zongertinib, pembrolizumab, cisplatin, carboplatin, pemetrexed
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
22
States / cities
Huntsville, Alabama • Bullhead City, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

NCT00300885
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 14, 2026, 11:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

NCT01770418
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Radiation with Concurrent Chemotherapy
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

NCT00024076
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
Interventions
radiofrequency ablation
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 14, 2026, 11:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

NCT06669117
View directory record Official record
Conditions
Solid Tumor, MET Alteration
Interventions
VERT-002
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Canton, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional

Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

NCT00057798
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, vinorelbine ditartrate, cytogenetic analysis, loss of heterozygosity analysis, microarray analysis, conventional surgery, neoadjuvant therapy
Drug · Genetic · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 14, 2026, 11:22 PM EDT